Else Kröner Forschungskolleg Cologne

Modern-day cancer therapy is witnessing a paradigmatic shift, away from globally toxic chemo- and radiotherapy, towards the use of non-genotoxic targeted small molecules and antibodies. These efforts are rooted in a steadily deepening molecular understanding of the patho-mechanisms underlying malignant transformation. The advent of modern technologies, particularly genome sequencing and novel approaches in high-performance computational biology, has revolutionized cancer research. These knowledge gains led to the development and clinical implementation of numerous novel drugs that specifically target genotype-stratified tumor entities. Prime examples are the use of specific tyrosine kinase inhibitors for EGFR-mutant-, EML4-ALK-rearranged- or ROS1-rearranged tumors, as well as BCR-ABL-fused leukemia.

These groundbreaking developments necessitate a profound change in the training and education of young oncologists. These physicians need solid clinical skills and a thorough training in molecular cancer research. Thus, we carefully assembled a peerless consortium of clinical opinion leaders and internationally competitive cancer researchers to create a structured training program for physician scientists that aim for a career in translational oncology.

Our consortium is tailored to address the question of clonal evolution and selection in response to targeted therapy. We consider this overarching question to be the major challenge in modern-day cancer therapy, as the majority of targeted approaches are eventually limited by the occurrence of acquired drug resistance. Our proposal is a cross-faculty joint effort of the members of the Center for Cancer and Immunology Research at the comprehensive cancer center of the University Cologne (CIO-CCIR) and also involves a non-university research center (Max-Planck-Institute for Metabolism Research). 


Mentors Program EKF Cologne

Program for the ekf-fellows Cologne

Julian Puppe´s Paper on EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy

Julian Puppe

The Else Kröner Forschungskolleg Cologne fellow Julian Puppe has published his paper in Clinical Cancer Research.

Sven Borchmann publishes paper on active surveillance in nodular lymphocyte-predominant Hodgkin lymphoma in Blood

The Else Kröner Forschungskolleg Cologne fellow Sven Borchmann has published his paper titled “Active surveillance for nodular lymphocyte-predominant...

Ron Jachimowicz´s paper on UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors is published

The Else Kröner Forschungskolleg Cologne fellow Ron Jachimowicz has published his paper in Cell.

Prof. Matthias Fischer publishes his work on the mechanistic classification of clinical phenotypes in neuroblastoma

Principal Investigator at the Else Kröner Forschungskolleg Cologne publishes in Sciene. The EKF fellow, Carolina Rosswog, has contributed to this...


Computational Biology Workshop, starting September 3th 2019

Workshop for the Else-Kröner-Forschungskolleg Cologne fellows

1st Amsterdam-Bern-Cologne-London Symposium, October 24th 2019

Targeting Defective DNA Repair in Breast Cancer

51st SIOP, October 23th -26th 2019

Congress of the International Society of Paediatric Oncology, Lyon, France

Bionano Genomics, October 16th 2019

Save the date for Dr. Georg Papoutsoglu from Bionano Genomics introducing its platform for whole genome mapping.

Cologne Cancer Club, October 2nd 2019

The role of the extracellular matrix architecture in melanoma proliferation and invasion

ESMO 2019 Congress, September 27th - October 1st 2019

Translating science into better cancer patient care